Summary:
This study evaluates the safety and efficacy of the investigational medication for the treatment of agitation associated with Alzheimer's Disease.
Qualified Participants Must:
Be between ages 55-90
have confirmed Alzheimer's Disease
have experienced agitation
and have a caregiver or other person who can attend visits with them
Qualified Participants May Receive:
Compensation for time and travel, including for the caregiver who attends visits with them